Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18FN3 |
| Molecular Weight | 295.354 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC2=C(NC3=C2CN(CCC4=CC=NC=C4)CC3)C=C1
InChI
InChIKey=PMXOASNGMJAYTN-UHFFFAOYSA-N
InChI=1S/C18H18FN3/c19-14-1-2-17-15(11-14)16-12-22(10-6-18(16)21-17)9-5-13-3-7-20-8-4-13/h1-4,7-8,11,21H,5-6,9-10,12H2
| Molecular Formula | C18H18FN3 |
| Molecular Weight | 295.354 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Carvotroline [WY 47791] is a novel γ-carboline derivative with a preclinical profile suggestive of antipsychotic activity. Carvotroline has an affinity for the dopamine D2 receptor and cortical 5-HT2 receptor that is ten times greater than serotonin. Carvotroline administration to rats leads to a decrease of plasma corticosterone levels and demonstrated a moderating effect on the rotational-stress induced rise in plasma corticosterone levels.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9323305
rat 7.0 mg/kg
Route of Administration:
Intraperitoneal
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:21 GMT 2025
by
admin
on
Mon Mar 31 18:20:21 GMT 2025
|
| Record UNII |
1Q63WWP8G5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10147990
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
72038
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
SUB06154MIG
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL300443
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
7057
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
107266-08-0
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
C109547
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
100000081351
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
1Q63WWP8G5
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY | |||
|
C79946
Created by
admin on Mon Mar 31 18:20:21 GMT 2025 , Edited by admin on Mon Mar 31 18:20:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|